▶ 調査レポート

世界の多血小板血漿市場

• 英文タイトル:Platelet Rich Plasma Market - Growth, Trends, and Forecast (2019 - 2024)

Mordor Intelligenceが調査・発行した産業分析レポートです。世界の多血小板血漿市場 / Platelet Rich Plasma Market - Growth, Trends, and Forecast (2019 - 2024) / C-MOR-100406資料のイメージです。• レポートコード:C-MOR-100406
• 出版社/出版日:Mordor Intelligence / 2019年8月
• レポート形態:英文、PDF、106ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥629,000 (USD4,250)▷ お問い合わせ
  Multi User¥703,000 (USD4,750)▷ お問い合わせ
  Site License¥888,000 (USD6,000)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、多血小板血漿の世界市場について調査・分析し、多血小板血漿の世界市場規模、市場動向、市場環境分析、市場展望、セグメント別分析、地域別分析、関連企業情報など以下の構成でお届け致します。

Market Overview
The global platelet-rich plasma market is expected to register a CAGR of approximately 14% over the forecast period. The key factors that are augmenting the growth of the market include rising incidences of sports injuries, increasing number of androgenic alopecia patients, growing use of platelet-rich plasma in various therapeutic areas, and rise in the prevalence of arthritis.

Osteoarthritis (OA) is the most common form of chronic disorder of the joints, and it has some detrimental effects on the quality of life of the patients. Progressive cartilage destruction, osteophyte formation, and subchondral sclerosis are characteristic to osteoarthritis. Platelet-rich plasma (PRP) is an autologous concentration of a high number of platelets in a small volume of plasma. PRP is prepared to centrifuge blood. In knee OA, PRP injections target to promote cartilage repair in order to relieve symptoms of osteoarthritis, hence delaying the need for joint replacement surgery.

The rising prevalence of the arthritis is augmenting the demand of the blood products, which is ultimately helping the growth of the platelet-rich plasma market.

Scope of the Report

As per the scope of the report, platelet-rich plasma (PRP) prolotherapy, like dextrose prolotherapy, is a method of injection designed to stimulate healing. Platelet-rich plasma is defined as autologous blood with concentrations of platelets above baseline levels, which contains at least seven growth factors.

Key Market Trends

Pure PRP Segment by Type is Expected to Hold the Largest Market Share

The pure PRP segment of the global platelet rich plasma market is believed to have the largest market share.

The prime factor responsible for the growth of this segment is the significance of this type of platelet plasma for the person. Pure PRP has an edge over traditional PRP, as it requires a two-step concentration process that helps in eliminating unwanted red blood cells (RBCs) and neutrophils. RBCs (that have no therapeutic effects for regeneration) can create a more viscous solution that can be more painful when injected. Neutrophils, a type of white blood cell, have inflammatory components that may increase pain and inflammation post-treatment.

Pure PRP helps the stem cells and regenerative cells in the repair and in rebuilding the damaged tissue. This ultimately speeds up the healing process and reduces pain. In addition, it promotes increased strength and improves the overall function. Therefore, owing to the contribution of pure PRP in the healing process and the rising use of it as a blood product, the segment is expected to dominate the market in the coming future.

North America Dominates the Market and is Expected to Continue the Same Trend for Next Few Years

North America currently dominates the platelet-rich plasma market and is expected to continue its stronghold for a few more years. The United States is a major market, and this is mainly due to the US government’s initiatives to develop blood products. In addition, the emergence and adoption of novel technologies are going to help the market in a positive manner.

Competitive Landscape

Companies, such as Biotest AG, China Biologic Products Inc., CSL Ltd, Octapharma AG, and LFB SA, are some of the key players operating in the global platelet-rich plasma market. With the advancement in technology, new players are expected to come in the market.

Reasons to Purchase this report:
The market estimate (ME) sheet in Excel format
Report customization as per the client’s requirements
3 months of analyst support

レポート目次

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidences of Sports Injuries
4.2.2 Increasing Number of Androgenic Alopecia Patients
4.2.3 Growing Use of Platelet-rich Plasma in Various Therapeutic Areas
4.2.4 Rising Prevalence of Arthritis
4.3 Market Restraints
4.3.1 Stringent Regulatory Policies
4.3.2 High Prices of Plasma Therapy
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Pure PRP
5.1.2 Leukocyte-rich PRP
5.1.3 Pure Platelet-rich Fibrin
5.1.4 Leukocyte-rich Fibrin
5.2 By Source
5.2.1 Autologous
5.2.2 Allogenic
5.3 By Application
5.3.1 Orthopedic
5.3.1.1 Arthritis
5.3.1.2 Chronic Tendinitis
5.3.1.3 Bone Repair and Regeneration
5.3.2 Dermatology
5.3.2.1 Androgenic Alopecia
5.3.2.2 Plastic Surgery
5.3.2.3 Cardiac Muscle Injury
5.3.2.4 Dental
5.3.2.5 Nerve Injury
5.3.2.6 Other Applications
5.3.3 By End User
5.3.3.1 Hospitals and Clinics
5.3.3.2 Research Institutes
5.3.3.3 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bio Product Laboratory Ltd (BPL)
6.1.2 Biolife Plasma Services
6.1.3 Biotest AG
6.1.4 Cambryn Biologics LLC
6.1.5 China Biologic Products Inc.
6.1.6 CSL Ltd
6.1.7 Grifols International SA
6.1.8 Kedrion SpA
6.1.9 LFB SA
6.1.10 Octapharma AG
7 MARKET OPPORTUNITIES AND FUTURE TRENDS